CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis

ObjectiveChimeric antigen receptor T-cell immunotherapy (CAR-T) is a preferred treatment for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Several trials have evaluated CD20×CD3 bispecific antibodies (BsAbs) as subsequent therapy in R/R LBCL. This study aimed to investigate the efficacy...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Shen, Jingyi Zhang, Zhengyu Zhu, Haobo Ma, Xiayan Li, Junpeng Zhang, Fan Zhou, Hua Tian, Jinghua Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Oncology
Subjects:
bispecific antibody
meta-analysis
CAR-T cell therapy
relapsed or refractory
large B-cell lymphoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1641769/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1641769/full

Similar Items